Insiders who reported open-market trades in the last 12 months at the companies Jing L. Marantz files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Mo Qatanani - $8.60M in SRRK purchases and sales in the last 12 months
David Hallal - $3.97M in SRRK purchases and sales in the last 12 months
Akshay Vaishnaw - $1.48M in SRRK purchases and sales in the last 12 months
Vikas Sinha - $1.23M in SRRK purchases and sales in the last 12 months
Keith Woods - $1.22M in SRRK purchases and sales in the last 12 months
Srinivas Akkaraju - $1.18M in SRRK purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Jing L. Marantz is a corporate insider, tracked as Director of Arcturus Therapeutics Holdings Inc. (ARCT). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Jing L. Marantz last file a Form 4?
The most recent primary Form 4 on record is dated 15 June 2026, one of 7 filings going back to 2024.
Has Jing L. Marantz been buying or selling stock?
Recorded transactions: 0 open-market purchases and 11 open-market sales ($3.81M) across all tracked filings.
Jing L. Marantz is Director of Arcturus Therapeutics Holdings Inc. (ARCT). 7 SEC Form 4 filings on record going back to 2024, most recently on 15 June 2026. Most recent open-market trade: sold $193K of SRRK on 19 February 2026. Lifetime open-market sales: $3.81M.
Recent transactions
16
The latest 16 SEC Form 4 transactions reported by Jing L. Marantz.
InsiderAlpha's records for Jing L. Marantz go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. 17 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
